Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung

被引:143
作者
Jooss, K
Yang, YP
Wilson, JM
机构
[1] WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104
[2] UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104
[3] UNIV PENN,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104
关键词
D O I
10.1089/hum.1996.7.13-1555
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Immune responses to adenovirus-mediated gene transfer contribute to the problems of transient recombinant gene expression, inflammation, and difficulties with vector readministration. Activation of CD4(+) T cells is required for full realization of effector function of both CD8(+) T cells (i,e,, cytotoxic T cells) and B cells (i,e,, neutralizing antibody), We evaluate in this study the effectiveness of a short course of high-dose cyclophosphamide to block immune responses in mice administered vector into lung and liver of C57BL/6 mice, Administration of cyclophosphamide with vector directed to liver blocked activation and mobilization of both CD4(+) and CD8(+) T cells, As a result, transgene expression was prolonged, inflammation was reduced, and, at the higher doses of cyclophasphamide, formation of neutralizing antibody was prevented and the vector was successfully readministered, Similar studies in the lung demonstrated an effective blockade of T and B cell responses, In contrast to the liver, where it was easier to stabilize transgene expression than to prevent neutralizing antibody, cyclophosphamide prevented the formation of neutralizing antibodies at all doses in the lung, whereas stabilization of transgene expression was only achieved at the highest dose, These experiments begin to define the parameters by which cyclophosphamide could be used as an adjunct in gene therapy.
引用
收藏
页码:1555 / 1566
页数:12
相关论文
共 27 条
  • [1] BARR D, 1995, GENE THER, V2, P151
  • [2] Berge RJ, 1994, NETHERLANDS J MED, V45, P329
  • [3] CHANG TKH, 1993, CANCER RES, V53, P5629
  • [4] CHEN L, 1995, CANCER RES, V55, P581
  • [5] CLARKE L, 1989, CANCER RES, V49, P2344
  • [6] TRANSFER OF GENES TO HUMANS - EARLY LESSONS AND OBSTACLES TO SUCCESS
    CRYSTAL, RG
    [J]. SCIENCE, 1995, 270 (5235) : 404 - 410
  • [7] CELLULAR AND HUMORAL IMMUNE-RESPONSES TO ADENOVIRAL VECTORS CONTAINING FACTOR-IX GENE - TOLERIZATION OF FACTOR-IX AND VECTOR ANTIGENS ALLOWS FOR LONG-TERM EXPRESSION
    DAI, YF
    SCHWARZ, EM
    GU, DL
    ZHANG, WW
    SARVETNICK, N
    VERMA, IM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) : 1401 - 1405
  • [8] ABLATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES TRANSGENE PERSISTENCE AND DECREASES INFLAMMATORY RESPONSE IN MOUSE-LIVER
    ENGELHARDT, JF
    YE, XH
    DORANZ, B
    WILSON, JM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) : 6196 - 6200
  • [9] GENE-THERAPY FOR HEMOPHILIA-B - HOST IMMUNOSUPPRESSION PROLONGS THE THERAPEUTIC EFFECT OF ADENOVIRUS-MEDIATED FACTOR-IX EXPRESSION
    FANG, B
    EISENSMITH, RC
    WANG, H
    KAY, MA
    CROSS, RE
    LANDEN, CN
    GORDON, G
    BELLINGER, DA
    READ, MS
    HU, PC
    BRINKHOUS, KM
    WOO, SLC
    [J]. HUMAN GENE THERAPY, 1995, 6 (08) : 1039 - 1044
  • [10] LONG-TERM HEPATIC ADENOVIRUS-MEDIATED GENE-EXPRESSION IN MICE FOLLOWING CTLA4LG ADMINISTRATION
    KAY, MA
    HOLTERMAN, AX
    MEUSE, L
    GOWN, A
    OCHS, HD
    LINSLEY, PS
    WILSON, CB
    [J]. NATURE GENETICS, 1995, 11 (02) : 191 - 197